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Metastasis – recent scientific insights and challenging
new therapeutic approaches
Abstract
Majority of cancer patients never die from the original disease – primary
tumor – but from the metastasis that disseminate throughout the body.
Although they disseminate in millions only few of them succeeded in their
journey and achieve their main goal – form a distant metastatic colony
which is able to thrive in an inhospitable environment of an unrelated
tissue. This review will summarize in brief some of the recent advances in
cancer invasion and metastasis investigations and possibilities in using these
findings for the benefit of cancer patients.
INTRODUCTION
Tumors kill the host when they start invading the surrounding tissue so90 % of patients that suffer from solid tumors actually die from
metastases which have a marked variety of clinical manifestations (1). In
breast cancer patients, metastasis can occur many years after the appear-
ance of the primary tumor while patients suffering from pancreatic cancer
or melanoma often die before the detection of the primary tumor. Colon
carcinoma patients live with detectible metastasis for decades, while child-
hood neuroblastoma metastases sometimes mysteriously disappear.
The risk of metastasis disease or metastatic recurrence can in some
cases be predicted by histopathological parameters such as: tumor size
or grade, presence or absence of certain gene/protein markers (2). How-
ever, in many cases this is not possible or is highly unreliable, therefore,
the search for relevant prognostic markers is one of the main goals of
researches in this field.
For decades it has been widely accepted that prediction of tumor
outcome is of utmost importance for metastasis prevention and ade-
quate surgical and/or other therapy. The latest developments in metasta-
sis research brings new evidence in this field and opens new possibilities
that could prevent metastatic spread but also offer new opportunities in
metastasis treatment when/if they occur. This way we hope that even if
a malignant tumor succeeds in spreading metastasis there will be tools
available to eradicate them or keep them quiescent. This way the
metastasis would, if not be cured at least be keep silent for many years.
This would not only prolong the overall life span of cancer patients but
also improve their quality of life.
The metastatic cascade
Our organisms are highly evolved systems whose tissues and organs
function in an extremly sophisticated manner; disobedience of a cell in
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means of wondering around the body or growing in
unfamiliar tissue without control is not to be tolerated.
However, some of the cells manage to escape the multi-
ple guardian mechanisms of the organism and fulfill this
task adopting certain physiological and morphological
changes which enable them to survive in circulation and
invade unfamiliar microenvironments.
In order to fulfill its destiny the metastatic cell has to
execute a complex series of events called the metastatic
cascade: it has to detach from the original tissue (tumor
cell dissociation), enter in the surrounding stroma (in-
vasion), enter into the microvasculature, blood or lymph
vessels (intravasation) after which it is passively carried
by the circulation until trapped in a capillary bed when it
begins to actively leave the circulation (extravasation)
attacking the foreign tissue (invasion) (3). Although pro-
bably millions of metastatic cells detach from the original
tumor tissue only very few of them actually manage to
survive all of the mentioned steps which is why meta-
stasis is considered to be a very ineffective process. Dur-
ing the metastatic cascade the cells can be destroyed in
the circulation flow or trapped in small vessels and de-
graded. They could also be attacked by the immune sys-
tem, or stay in a dormant state for many decades.
Epithelial-mesenchymal transition
Carcinomas, malignancies of epithelial origin, en-
compass 80 % of all tumors. Epithelial cells embed in-
ternal organs or form upper skin layers protecting the
body from injuries and infection. They form unicellular
or multicellular layers which means they are tightly mu-
tually connected and incapable of migration (4). To be-
come invasive they have to adopt the ability to move
which requires basic cellular transcriptional reprogram-
ming which will eventually make them more similar to
mesenchymal, fibroblast-like cells. This process is called
epithelial-mesenchymal transition (EMT) (5). EMT is a
normally active process in the body essential for wound
healing (6) but even more important in embryogenesis
during gastrulation (7) or the formation of the neural
crest. In the case of tumor invasion it is, however, a
pathological process driven by genetic and epigenetic
abberations leading to seriously deregulated cellular sig-
naling. Transforming through the EMT the epithelial
cell changes its shape to a fibroblast-like cell, becomes
motile and invasive, looses its apical-basal polarity and
changes a number of cellular markers (Figure 1). The
crucial change that occurs in this transformation is the
downregulation of E-cadherin. E-cadherin is a calcium
dependent, transmembrane glycoprotein expressed at the
basolateral membrane of the epithelial cell. It is a core
point of adherens junctions which anchor the cell in the
epithelial layer by forming homodimer connections be-
tween neighboring cells. With its intracytoplasmic tail
E-cadherin is linked to the actin cytoskeleton through a,
b and g-catenins as well as p120. The loss of functional
E-cadherin not only encourages the tumor cell to dis-
engage from its original tissue and change its shape but
also releases b catenin from the complex. Upon disinte-
gration from the complex the free b catenin translocates
to the nucleus and activates the Tcf/Lef transcriptional
program which initiates the EMT. The activation of the
EMT program (8) induces the secretion of another mem-
ber of the cadherin family, the N-cadherin. N-cadherin
also forms homotipic connections between neighboring
cells but also with the stromal cells underlying the epi-
thelial layer. These connections are loose and enable the
cells from the epithelial layer to escape their domestic
tissue and by connecting with the stromal cells make a
passage through the stroma to the blood or lymphatic
vessel (9). Once available to the stromal factors (TGF b,
TNF a, EGF, HGF, IGF-1) the cells are constantly
under their influence rendering them highly motile and
invasive. The growth factors act either on their own or in
synergism in different combinations and with the help of
the mutated Ras oncogene maintain the EMT program.
Although the complete mechanism of EMT is not yet
revealed it is known that several transcription factors like
Snail, Slug, Zeb and Twist can work as repressors of
E-cadherin (10, 11). The activation of EMT transcrip-
tion factors can also prevent apoptosis and anoikis (sur-
fice detachement induced cell death) or deregulate in-
tegrin expression.
The EMT program is not necessarily irreversible. Since
EMT appears as a consequence of both genetical chan-
ges and the influence of the microinvironment, after
disembarking in a distant tissue the altered microin-
vironment (growth factors, cytokines and components of
the extracellular matrix) can lead to a reverse process –
mesenchymal-epithelial transition (MET) which changes
the cell back to an epithelial one (12).
Whether EMT is an obligatory process in turning a
normal cell into a malignantly transformed one also has
its skeptics (13). Tumor cells are a heterogeneous and
changing population with different morphological and
physiological properties. It is, however, probable that the
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Figure 1. Epithelial-mesenchymal transition (EMT). A process
characterized by loss of cell adhesion, repression of E-cadherin
expression, and increased cell motility – a prerequisite for invasive
phenotype.
cells on the „leading edge” must go trough this trans-
formation to be able to clear the way though the stroma
to the blood or lymph vessel. It is nowadays suggested
that the cells in the leading edge while passing through
the extracellular matrix form a tunnel of least resistance
which enables the other cancer cells to massively, col-
lectively follow (14, 15). The collective is, therefore, com-
posed of invasive, motile, integrin b1 expressing, guiding
cells on the invasive front and a patch of tumor cells of
various phenotypes that didn’t, necessarily, experience
the EMT on the rear (16, 17). Numerous studies have
documented that the majority of circulating tumor cells
(CTCs) that have been released in the blood stream do
not form metastases. It is, however, possible that these
cells, for example, have a role in forming a specific „niche”
for potent metastatic cells. By secreting favorable growth
factors during their voyage through the body CTCs con-
dition specific tissues and make them convenient for
growth of metastatic cells.
Cancer stem cells – the origin of
metastatic cells?
The origin of cancer cells was for decades thought to
be a product of several or numerous mutations eventu-
ally acquiring features of a transformed phenotype: un-
controlled growth, morphological changes and in the
end, certain migration and invasion potential. Widely
accepted stochastic model defines metastatic cells as a
subpopulation of cells that accumulate changes over time
which enables them to detach from the original tissue
and invade the surrounding stroma as well as give them
selective advantages that made them robust enough to
survive in circulation and colonize a distant tissue. The
discovery of cancer stem cells shed new light to the pos-
sible origin of cancer and cancer metastasis (Figure 2).
Cancer stem cells (CSC) are a rare subpopulation of
cancerous cells that are defined by three major features:
they give rise to tumors, they are capable of selfrenewal
and have a pluripotent nature (18). The cancer stem cell
model proposes that only these particular cells are res-
ponsible for tumor renewal and seeding. Cancer stem
cells were first identified in hematological malignancies
(19) but are most extensively studied in breast, prostate
and pancreatic tumors (20). CSCs in every particular
tumor bear specific surface markers, for example, breast
cancer stem cells are distinguished from the rest of the
tumor population by CD44+ CD24low phenotype, whe-
reas brain CSCs obtain a CD133+ Lin- phenotype. This
is also one of the possible ways how CSCs can be isolated
from the rest of the tumor cell population. These cells are
considered to be resistant to chemotherapy which mas-
sively kills highly proliferating cells. CSCs are known to
be quiescent and therefore escape conventional therapy.
It is thought that this fact is actually the base for tumor
relapse. If this hypothesis proves to be correct than CSCs
are certainly candidate cells for seeding metastasis, as
well (21). The recent work of Mani et al. demonstrated a
link between the EMT and cancer stem cells (22). By
inducing EMT in immortalized human mammary epi-
thelial cells (HMLEs) treating them with TGFb or induc-
ing Snail or Twist transcription factors most of the cells
acquire stem cell like characteristics including CD44+
CD24low phenotype. Overexpression of Snail or Twist
together with V12H-Ras oncogene is sufficient to make
them tumorigenic and capable of forming a small tumor.
Their result suggests that initiating EMT (the earliest
step in metastasis formation) in cells leads to CSC-like
cells which could be a link between CSCs and metastatic
cells. There is no direct evidence that this is really the
case. It is, however, suggested that not all CSCs have the
metastatic capacity but probably only a certain subpo-
pulation (21).
Metastasis suppressor genes
The group of metastasis suppressor genes (MSGs)
were established after the identification of the first meta-
stasis suppressor gene in 1988 (23) by Steeg and colla-
borators. Metastasis suppressor genes specifically regula-
te metastasis i.e. one or more steps in the metastasic
cascade: detachment, invasion, migration, survival in
circulation, invasion of the secondary site, colonization.
Most MGS exhibit decreased expression in highly meta-
static tumors vs. their non-metastatic primary tumors.
Restoration of a MSG does not effect the primary tumor
growth. Tumor cells expressing the MSG grow on the
primary site but cannot colonize distant sites in the body
(24). Based on this definition in the last couple of years as
much as 30 or more metastasis suppressor genes have
been identified. Nevertheless, mechanisms of action of
these genes/ proteins are mostly still not understood.
Metastasis suppressor are found to have different subcel-
lular localizations while some of them are even present in
the extracellular matrix (25). For instance the first identi-
fied MSG Nm23 (Nme) is mostly localized in the cyto-
plasm but can also be found colocalizing with several
different intracellular structures (26). The E-cadherin is a
plasma membrane bound molecule while MKK4, MKK7
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Figure 2. Two different models defining tumor promotion, recurrence
and secondary tumor appearance. The stochastic model implies that
every tumor cell has the ability to form a new tumor while the cancer
stem cell model presumes that not all tumor cells are tumorigenic but
only the cancer stem cells (CSC) which are a small population within
the tumor mass.
or RhoGDI2 are typical cytoplasmic signaling molecules.
Many of the metastatic suppressors are multifunctional
enzymes with clear functions that have up until recently
had nothing to do with metastatic activity (caspase 8)
(27). As already metioned, MSGs suppress metastasis at
one or more steps in the metastatic cascade. Some of
them, like E-Cadherin, promote homotypic cell-cell ad-
hesions and are, therefore, hindering tumor cell dis-
sociation. Most of them suppress the invasion of local
tissue and intravasation (gelsolin, RKIP,CD44, Claudin-
-4) while other impair survival in the circulation (caspase
8, DCC). Some of them exhibit their function in pre-
venting the survival and proliferation of the micro-
metastasis (MKK4, MKK7, Smad7). Several metastasis
suppressors are possibly involved in two or more steps in
the metastatic cascade Nm23, KAI1, Kiss1, BRMS1,
RhoGD1) (28).
Tumor dormancy
Once anchored in a distant site the metastatic cell can
experience several different fates: a) it can die of apo-
potosis; b) remain in a quiescent (G0/G1) state as a single
solitary cell (cellular dormancy); c) remain dormant as a
micrometastatic cluster (metastatic/angiogenic dorman-
cy) or d) proliferate and form a detectible metastatic
colony (29).
In general, cancer dormancy is a stage in tumor pro-
gression in which tumors remain in dormant micro-
scopic and clinically asimptomatic stage for a long time.
Dormant tumors are often only a few milimeters in
diameter but they can switch to highly proliferating
growing lesions which can become clinically relevant
and lethal in a very short period of time. It is of great
clinical significance that recent studies display that can-
cer can produce disseminating cells in a very early stage
of primary tumor development and that dormant tumors
(micrometastases) can actually be present very early in
tumor progression (30). It is even hypothesized that most
of the tumors disseminate in a very early stage but the
disseminated cells stay dormant for decades (31). The
escape of tumors from dormancy is still a puzzle but it is
widely accepted that the main reason for this phenome-
non lies in the fact that the dormant mass of tumor cells
fails to reconstruct functional vasculature. The mass grows
to a certain size but the tumor expansion relies on suf-
ficient nutrition supply so cells, although possibly highly
proliferative, die of apopotosis due to malnutrition. The
transition from the unvascularized lesion to a highly
vascularized growing tumor mass is called the angiogenic
switch. The reason why these small primary or metastatic
tumors fail to form functional vasculature remains to be
investigated but it is known that dormant tumors secrete
relatively high levels of potent angionic inhibitor called
thrombospondin (32). It is, however, to be considered that
there are other mechanisms that can contribute or even
be crucial for tumor dormancy. Tumor development is a
complicated multistage process which depends on a well
tuned series of biochemical and biological events. It has
been shown that large proportion of cells remains in
distant locations as single dormant cells. This is probably
due to inhospitable environment of the host tissue which
does not support the proliferation of the unrelated cell
due to interactions with the extracellular matrix compo-
nents and stromal cells. Solitary tumor cells or small
tumor masses can also be a target of immunosurveilance
or be influenced by hormonal control or autophagy. Dor-
mancy can be induced by activation of metatasis sup-
pressor genes responsible for this step in the metastatic
pathway. The proposed mechanisms of action of these
suppressors include either activation of p38/MAPK or
inhibition of ERK1/2 MAPK pathways. These mecha-
nisms can be linked to angiogenesis as a major control
mechanism but can possibly also be unrelated (33).
New directions in therapy
Treatment of metastatic cancer is one of the major
challenges in tumor management. Unlike primary tu-
mor lesions, metastasis are often inoperable and thus the
choice of treatment is dependent on tumor type and stage
and includes chemotherapy, hormonal therapy, targeted
therapy and radiotherapy. Due to the cascade nature of
metastatic spread, targeting any of the distinct steps would
successfully prevent overt metastatic disease. Unfortuna-
tely, at time of diagnosis most cancer patients already
harbor disseminated tumor cells in lymph nodes, circula-
tion, bone marrow or distant organ sites (34). Thus,
development of treatment should be targeted at the colo-
nization step of metastasis, preventing growth of solitary
disseminated cells or micrometastasis into clinically sig-
nificant metastasis (35, 36). Major effort to develop can-
cer drugs was dedicated to eradicate tumor cells using
chemotherapy and radiotherapy adjuvant to surgery, but
disseminated cancer cells are often resistant to such the-
rapy due to dormancy at distant sites or stem-cell like
properties (36, 37). In addition, therapeutics targeted at
specific pathways in primary tumor cells may not be
efficient for managing metastasis due to genetic and
expression differences. During the initial seeding of tu-
mor cells at a distant organ site and development of
micrometastasis, cells undergo changes in order to adopt
to the new microenvironment, rendering them different
from primary tumor cells and thus resistant to targeted
therapy directed against the primary tumor (38). Broaden-
ing the knowledge of metastatic cells specific properties is
essential for designing novel targeted therapies. Novel
imaging techniques as well as better detection and eva-
luation of metastatic gene and expression signatures led
to improvement of detection of distant metastasis and
disseminated tumor cells in circulation and bone marrow.
This enabled assessment for clinical usefulness: diagno-
stic, prognostic and therapeutic potential (34, 38, 39). As
stated, the colonization step is the most promising target
process in metastasis. Since the discovery of nm23, the
first characterized metastasis suppressor gene, this group
of proteins pose an intriguing opportunity to develop
anti-metastatic therapy. The most interesting members
include KISS1, KAI1, MKK4/7 and Nm23, which can
promote dormancy (33). In animal metastatic models,
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cancer cells with induced expression of these genes dissemi-
nate but do not develop overt metastasis. KISS1 and KAI1
promote cellular dormancy while Nm23 and MKK4/7
support dormancy at the micrometastasis level (40–43).
Lack of MSG function in metastatic cells is usually due
to downregulation, rarely to mutation. That is why main
therapeutic approach should include re-establishment of
MSG expression in disseminated cells (44). The benefit
of promoting metastatic dormancy by inducing trans-
criptional activation of Nm23 by medroxyprogesterone
(MPA) is currently being tested in phase II clinical trial.
The main objective of the trial is determining the be-
nefits of MPA monotherapy and MPA and low dose
cyclophosphamide and methotrexate in postmenopausal
patients with refractory – hormone receptor-negative
metastatic breast cancer. During the trial, expression of
Nm23 will be evaluated in biopsies of primary tumor,
metastasis and skin to assess potential correlation be-
tween Nm23 and growth of metastases (45). Beside me-
tastatic cells’ intrinsic mechanisms, tumor associated mi-
croenvironment at distant sites offers valuable targets for
metastasis therapy. Fibroblasts, endothelial cells and ma-
crophages secrete soluble factors (cytokines, growth factors)
that can either promote growth or induce dormancy.
Illustrative example is the interplay between disseminat-
ed cells and bone microenvironment in development of
bone metastasis. Tumor cells secrete osteoblastic and os-
teoclastic factors that increase bone turn-over and release
of growth factors from bone matrix that stimulate tumor
growth creating a positive feedback loop (46). Based on
preclinical data, osteoclast inhibitors that may interrupt
that cycle are developed. Osteoclast inhibitors: denosumab
(RANKL inhibitor) and zoledronic acid (bisphospho-
nate) are already used to treat overt metastasis (47), and
currently ongoing clinical trials asses the possibilities of
using these drugs adjuvant to primary tumor treatment
in order to prevent or delay development of metastases
(48).
Another useful target is angiogenesis. Rationale for
anti-angiogenic therapy in metastatic cancer is to prevent
vascularization of micrometastasis thus inhibiting growth
or to prevent intravasation and secondary spread of can-
cer. Currently, inhibitors of VEGF pathway combined
with chemotherapy are approved by FDA for treatment
of metastatic breast cancer, metastatic renal carcinoma
and colon cancer (49). Bevacizumab, monclonal anti-
-VEGF antibody and receptor tyrosine kinase inhibitors:
sunitinib and sorafenibin are shown to increase disease-
-free and overall survival in most clinical trials (50).
However, after initial growth inhibition by VEGF inhi-
bitors, regrowth of tumor or distant metastasis is often
observed (50–52). In addition, recent preclinical studies
show that administration of these drugs can enhance
more aggressive and metastatic phenotype (53, 54). Thus,
anti-angiogenic therapy for treatment of early dissemi-
nated cells and micrometastases should be carefully reas-
sessed, taking into consideration both the benefits and
limitations, depending on tumor type, stage and accom-
panying therapy. Apart from the already mentioned ap-
proaches there are numerous perspective drugs develop-
ed for targeting other processes connected to metastasis:
EMT (55), invasion, intravasation/exstravasation, disse-
mination and colonization (56), immune axis (57), mi-
croenvironment and tumor stem cells (37, 47, 58). Con-
sidering the evidence we have today, it is clear that
therapies aimed specifically at prevention of clinically
significant metastasis needs to be administrated at the
time of cancer diagnosis, either adjuvant or neo-adjuvant
to primary treatment. Although metastatic cells eradi-
cation is the considered favorable treatment end-point,
inducing or prolonging dormancy of metastatic cells and
micrometastasis could represent a new treatment
strategy that would turn cancer into a chronic disease
and reduce mortality.
CONCLUSION
Cancer represents one of the major health challenges
in the 21 century. Inspite of great financial imputes in the
last decades we are still in the process of searching for
answers how to manage this disease. Lately, the scientific
community has done significant contributions in under-
standing the mechanisms not only of cancer onset but on
its dissemination and metastatic colonization. The find-
ings we represented in this review are only a part of the
extensive studies which demonstrate that many of the
postulates that have been taken for granted in the past
should probably be redefined. Still, much effort should
be put in proving the novel concepts in vivo. However,
concerning the fact that cancer patients mostly die from
metastasis it seams rational to focus particularly on this
step in carcinogenesis which will hopefully bring us
valuable new therapeutic approaches.
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